Bracco (company)
| Type | Private |
|---|---|
| Industry | Chemical, pharmaceutical |
| Founded | 1927 |
| Founder | Elio Bracco |
| Headquarters | |
Area served | Worldwide |
| Key people | Diana Bracco (President and CEO of the Bracco Group) Fulvio Renoldi Bracco (Vice Chairman and CEO of Bracco Imaging) |
| Products | Contrast agents, injectors, medical devices, pharma |
| Revenue | |
Number of employees | 4,000 (2024) |
| Website | www |
The Bracco Group is an Italian multinational active in the healthcare sector, specialized globally in diagnostic imaging. The company has a workforce of over 4,000 employees and consolidated annual revenues of approximately €2 billion, 88% generated by international markets.
In Research and Development, the company allocates approximately 9% of its reference turnover in the imaging diagnostics and medical devices sectors, maintaining a portfolio of over 2,500 patents and 11 innovation centers across the world. Diana Bracco serves as President and CEO, and Fulvio Renoldi Bracco as Vice-President and CEO of Bracco Imaging.
The company’s portfolio includes pharmaceutical products for diagnostic imaging, including contrast agents for X-ray, Computed Tomography (CT), and Magnetic Resonance Imaging (MRI), as well as microbubbles for Contrast Enhanced Ultrasound (CEUS), and Molecular Imaging through radioactive tracers and PET imaging agents, alongside AI-based applications. Bracco Group also develops contrast management technologies for cardiovascular angiography and radiology imaging.
In Italy, Bracco Group established the CDI - Centro Diagnostico Italiano, an outpatient healthcare provider specialized in prevention, diagnosis, and rehabilitation services. The Group operates in over 100 countries both directly and through subsidiaries, joint ventures, and licensing or distribution agreements, with significant market presence in North America, China, Europe, and Japan.
Historically, the Bracco brand in Italy is associated with pharmaceutical products such as Cebion, Xamamina, Euclorina, the Alfa eye-drops line, and the Friliver range of sport supplements. services. In 2016, Bracco sold its pharmaceutical division to the Italian biopharmaceutical group Dompé. The divestment allowed Bracco to focus on its core business of diagnostic imaging.